Finlands Akademi  
 
 
 
 
 
Finansieringsbeslut
 
Sökande / Kontakt person Saksela, Kalle
Organisation Helsingfors universitet
Projektets titel Improved CAR-T cell targeting of cancer
Beslutnr 331787
Beslutsdatum 27.05.2020
Finansierings period 01.09.2020 - 31.08.2024
Finansiering 518 340
   
Beskrivning av projektet
Chimeric antigen receptor (CAR)-T cell therapy is a promising new approach for treating cancer, where an engineered CAR molecule is introduced into patient's immune cells to direct them to destroy cancer cells. CAR-T cell therapy has been very successful in treating leukemias and lymphomas. However, most cancers lack any truly cancer-specific determinants, and it has been difficult to create CAR-T cells that would efficiently kill cancer without attacking healthy tissues. Our laboratory has developed a new and highly tunable targeting technology based on a small protein module, known as the SH3 domain. We have already shown that using modified SH3 domains it is possible to create CAR-T cells that can sense even relative differences between cancer and normal cell surface structures. Here we propose a series of experiments designed to exploit this opportunity in order to develop potent but safe CAR-T cell therapies for ovarian and other cancers that have remained difficult to treat.